AI-generated research brief — verify at source
Patiromer Shows No Added Benefit Over Placebo for Acute Hyperkalaemia in Emergency Settings
In a randomised, double-blind, placebo-controlled trial across 16 US emergency departments, patiromer added to standard combination therapy produced no statistically significant improvement in net clinical benefit or potassium reduction at 6 hours compared with placebo (-0.6 vs -0.4; p=0.44). The trial was terminated early and remained substantially underpowered, meaning a true treatment effect cannot be excluded.
What Was Studied
This trial examined whether patiromer — a non-absorbed potassium binder approved for chronic hyperkalaemia management — could provide additional benefit when given alongside standard acute care in emergency department patients presenting with severe hyperkalaemia (serum potassium ≥5.8 mEq/L). The role of potassium binders in the acute setting has been poorly defined, creating clinical uncertainty about whether initiating them early might reduce the need for further interventions or accelerate potassium normalisation.
How It Was Studied
The PLATINUM trial was a prospective, randomised, double-blind, placebo-controlled study conducted across 16 emergency department sites in the United States. Adults aged 18 or older with confirmed serum potassium of at least 5.8 mEq/L were enrolled and randomised 1:1 to receive standard combination therapy — comprising 25 g intravenous dextrose, 5 units intravenous insulin, and 10 mg inhaled albuterol — with either patiromer or matching placebo. The first dose was administered within one hour of the potassium result, with a second dose given at 24 hours. A total of 111 patients were analysed (53 patiromer, 58 placebo), representing a fraction of the prespecified target sample size, as the trial was terminated early. Mean baseline potassium was 6.5 mmol/L, and key subgroups included patients on chronic haemodialysis (22.5%).
What Was Observed
- The primary endpoint — net clinical benefit at 6 hours, defined as the change in number of potassium-lowering interventions minus change in serum potassium — was nearly identical between the patiromer and placebo groups (-0.6 vs -0.4), with no statistically significant difference (p=0.44). This composite measure showed no advantage for the addition of patiromer under acute conditions.
- Serum potassium levels at the 2-, 4-, and 6-hour time points were numerically similar across both groups (5.50 vs 5.70, 5.45 vs 5.65, and 5.50 vs 5.60 mmol/L, respectively), with no statistically significant differences at any time point (all p>0.05). These findings suggest that patiromer did not accelerate potassium reduction relative to standard therapy alone.
- The number of additional potassium-lowering interventions required per patient was also similar between groups at each measured time point (p>0.05), indicating no reduction in rescue treatment burden with patiromer use.
- Adverse events were numerically more frequent in the placebo group than the patiromer group (32.76% vs 16.98%), but this difference did not reach statistical significance (p=0.08), meaning it may reflect chance variation in this small sample rather than a true safety signal in either direction.
Why This Matters
Hyperkalaemia is a potentially lethal electrolyte disturbance encountered frequently in emergency settings, and there is ongoing interest in whether newer potassium binders might complement redistributive therapies to improve patient outcomes. The PLATINUM trial represents one of the few prospective randomised efforts to evaluate this question under emergency conditions, making its design notable even if its results are inconclusive. The absence of observed benefit — alongside the early termination — highlights the methodological challenges of conducting acute electrolyte trials and underscores that the role of patiromer in this context remains unanswered.
How to Read This Result
Because the trial was terminated early and enrolled only a fraction of the planned sample, it was explicitly underpowered, meaning a clinically meaningful effect of patiromer cannot be ruled out and the null result should not be interpreted as definitive evidence of equivalence.
Limitations
The most consequential limitation acknowledged by the authors is early termination, which left the study substantially underpowered to detect a statistically significant treatment effect. The relatively small final sample of 111 patients — across a heterogeneous population that included a notable proportion of chronic haemodialysis patients — further constrains the generalisability and interpretive weight of the findings.